Fragasso Financial Advisors Inc Buys 9,102 Shares of Merck & Co., Inc. $MRK

Fragasso Financial Advisors Inc boosted its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 73.3% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 21,523 shares of the company’s stock after acquiring an additional 9,102 shares during the quarter. Fragasso Financial Advisors Inc’s holdings in Merck & Co., Inc. were worth $3,134,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. BlackRock Inc. lifted its position in Merck & Co., Inc. by 0.5% during the 2nd quarter. BlackRock Inc. now owns 226,999,837 shares of the company’s stock worth $29,169,479,000 after acquiring an additional 1,073,507 shares during the last quarter. State Street Corp raised its stake in Merck & Co., Inc. by 0.9% during the second quarter. State Street Corp now owns 120,413,256 shares of the company’s stock worth $15,573,754,000 after acquiring an additional 1,087,583 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Merck & Co., Inc. by 2.3% in the second quarter. Wellington Management Group LLP now owns 86,249,283 shares of the company’s stock valued at $11,083,033,000 after acquiring an additional 1,934,312 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Merck & Co., Inc. by 10.5% in the 1st quarter. Bank of America Corp DE now owns 30,774,221 shares of the company’s stock worth $3,701,831,000 after acquiring an additional 2,919,780 shares in the last quarter. Finally, Invesco Ltd. grew its holdings in Merck & Co., Inc. by 3.5% during the 4th quarter. Invesco Ltd. now owns 20,546,185 shares of the company’s stock worth $2,162,691,000 after acquiring an additional 701,249 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on MRK shares. TD Cowen boosted their target price on Merck & Co., Inc. from $137.00 to $155.00 and gave the stock a “hold” rating in a research report on Wednesday, September 23rd. Wolfe Research upped their target price on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. Wells Fargo & Company boosted their target price on Merck & Co., Inc. from $150.00 to $170.00 and gave the stock an “overweight” rating in a research report on Friday, September 4th. Leerink Partners lifted their price objective on shares of Merck & Co., Inc. from $127.00 to $161.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. Finally, Sanford C. Bernstein boosted their price target on shares of Merck & Co., Inc. from $100.00 to $105.00 and gave the company a “market perform” rating in a report on Tuesday, August 4th. Seventeen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $151.92.

Merck & Co., Inc. Stock Performance

MRK traded down $2.22 during trading on Tuesday, hitting $143.23. The stock had a trading volume of 2,787,578 shares, compared to its average volume of 10,600,905. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.32 and a quick ratio of 1.10. The company has a 50 day moving average price of $144.25 and a 200-day moving average price of $128.57. Merck & Co., Inc. has a one year low of $82.01 and a one year high of $156.92. The firm has a market cap of $353.37 billion, a price-to-earnings ratio of 114.62, a P/E/G ratio of 6.58 and a beta of 0.21.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%. The company had revenue of $16.61 billion for the quarter, compared to analysts’ expectations of $16.37 billion. During the same quarter last year, the business earned $2.13 earnings per share. Merck & Co., Inc.’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, research analysts predict that Merck & Co., Inc. will post 2.66 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th were given a dividend of $0.85 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.4%. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck will present first-time results from three pivotal Phase 3 oncology trials at the ESMO 2026 Congress, alongside more than 90 additional abstracts covering over 20 tumor types. The event could provide visibility into the company’s pipeline and help support confidence in future growth. Merck ESMO 2026 announcement
• Positive Sentiment: Industry reports point to continued expansion in bioprocessing, cell culture, protein labeling and bioconjugation markets—areas in which Merck’s life-science business participates. These reports suggest a favorable long-term demand backdrop, although they do not represent new company-specific guidance. Global cell culture market report
• Neutral Sentiment: Citigroup raised its price target to $145 while maintaining a neutral rating, indicating limited near-term upside at the cited valuation. Royal Bank of Canada lowered its target to $145 and kept a sector-perform rating, reflecting a more cautious outlook. Analyst price target updates
• Negative Sentiment: Jefferies cut its peak sales forecast for remigromig by 60% after detailed diabetic macular edema data showed the drug was statistically non-inferior to Lucentis but delivered smaller numerical vision improvements and raised safety concerns. The downgrade increases doubts about the drug’s commercial potential. Jefferies remigromig sales forecast
• Negative Sentiment: Erste Group Bank modestly reduced its FY2026 EPS estimate to $2.73 from $2.75 and its FY2027 estimate to $9.47 from $9.52. While the cuts are small, they add to near-term earnings caution. Merck analyst earnings estimates

Insider Buying and Selling at Merck & Co., Inc.

In other news, EVP Richard Deluca sold 11,699 shares of the company’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $131.63, for a total transaction of $1,539,939.37. Following the transaction, the executive vice president owned 110,167 shares in the company, valued at approximately $14,501,282.21. This represents a 9.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Chirfi Guindo sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $135.00, for a total value of $1,350,000.00. Following the sale, the executive vice president owned 36,613 shares of the company’s stock, valued at approximately $4,942,755. This represents a 21.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 228,238 shares of company stock valued at $29,977,783 over the last ninety days. Insiders own 0.17% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops and markets prescription medicines, vaccines, and animal-health products. The company serves patients, healthcare providers, and customers in markets around the world, with research and commercial operations spanning multiple geographic regions.

Its pharmaceutical portfolio includes oncology, infectious-disease, cardiovascular, immunology, and other therapeutic areas. Key products include Keytruda, an oncology treatment; Gardasil, a human papillomavirus (HPV) vaccine; Januvia and Janumet for type 2 diabetes; Bridion for anesthesia-related use; and Winrevair for pulmonary arterial hypertension.